63 results
424B3
KANT
Kineta, Inc.
13 Nov 23
Prospectus supplement
5:28pm
of our Common Stock, including any voting rights, until the holder exercises the warrant.
Resale Registration Rights
We have filed this registration
8-K
EX-4.3
KANT
Kineta, Inc.
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior
8-K
EX-4.2
KANT
Kineta, Inc.
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
8-K
EX-4.1
r9ql 26lsd
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
sarwihoygf
5 Oct 23
Prospectus supplement for primary offering
10:47am
424B3
94b7nmeu0inm
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-4.2
23b0hc53u64iahvx
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-4.1
9tco82w9nynkrxe1qgz
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-4.3
ygmzehon81x7zfn3y
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
mu8waesa33 0oaeb
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-3.3
etooclg1kz8d66rw7
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-10.6
w3y554 4g4xuhg9o
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm